P516 Efficacy and safety of tofacitinib retreatment for ulcerative colitis after treatment interruption: Results from the OCTAVE clinical trials
Julián Panés(Hospital Clínic de Barcelona), Chunyan Su(Peking University), N Lawendy(Pfizer (United States)), Brian Bressler(University of British Columbia), Deborah Woodworth(Pfizer (United States)), J F Colombel(European CanCer Organisation), Geoffrey Chan(The University of Texas System), H Zhang(Pfizer (United States)), Eric Maller(Pfizer (United States)), Leonardo Salese(Johnson & Johnson (United States))
Cited by 7
Related Papers
Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease
|New England Journal of Medicine|2013|2.7k
Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target
|The American Journal of Gastroenterology|2015|1.8k
Imaging techniques for assessment of inflammatory bowel disease: Joint ECCO and ESGAR evidence-based consensus guidelines
|Journal of Crohn s and Colitis|2013|669
Rates of New or Missed Colorectal Cancers After Colonoscopy and Their Risk Factors: A Population-Based Analysis
|Gastroenterology|2007|627
Ofatumumab As Single-Agent CD20 Immunotherapy in Fludarabine-Refractory Chronic Lymphocytic Leukemia
|Journal of Clinical Oncology|2010|587